Increased soluble Fas-ligand in sera of bone marrow transplant recipients with acute graft-versus-host disease

[1]  S. Nagata,et al.  Downregulation of Fas ligand by shedding , 1998, Nature Medicine.

[2]  J.W. Lee,et al.  Difference in the expression of Fas/Fas-ligand and the lymphocyte subset reconstitution according to the occurrence of acute GVHD , 1997, Bone Marrow Transplantation.

[3]  K. Yoshino,et al.  A metalloproteinase inhibitor prevents lethal acute graft-versus-host disease in mice. , 1997, Blood.

[4]  K. Elkon,et al.  A major role for the Fas pathway in acute graft-versus-host disease. , 1996, Journal of immunology.

[5]  E. Podack,et al.  The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice , 1996, The Journal of experimental medicine.

[6]  A. H. Drummond,et al.  Fas ligand in human serum , 1996, Nature Medicine.

[7]  K. Akashi,et al.  Serum concentration of the soluble interleukin-2 receptor for monitoring acute graft-versus-host disease. , 1996, Bone marrow transplantation.

[8]  J. Tschopp,et al.  Cytotoxic T cells deficient in both functional fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease , 1996, The Journal of experimental medicine.

[9]  A. Kawasaki,et al.  Metalloproteinase-mediated release of human Fas ligand , 1995, The Journal of experimental medicine.

[10]  S. Nagata,et al.  The Fas death factor , 1995, Science.

[11]  J. Inazawa,et al.  Human Fas ligand: gene structure, chromosomal location and species specificity. , 1994, International immunology.

[12]  P. Golstein,et al.  T cell receptor‐induced Fas ligand expression in cytotoxic T lymphocyte clones is blocked by protein tyrosine kinase inhibitors and cyclosporin A , 1994, European journal of immunology.

[13]  P. Tiberghien,et al.  Phase I-II trial of a monoclonal anti-tumor necrosis factor alpha antibody for the treatment of refractory severe acute graft-versus-host disease. , 1992, Blood.

[14]  P. Tiberghien,et al.  Soluble CD8, IL-2 receptor, and tumor necrosis factor-alpha levels in steroid-resistant acute graft-versus-host disease. Relation with subsequent response to anti-IL-2 receptor monoclonal antibody treatment. , 1991, Transplantation.

[15]  J. Bergerat,et al.  Treatment of corticosteroid resistant acute graft-versus-host disease by in vivo administration of anti-interleukin-2 receptor monoclonal antibody (B-B10) , 1990, Blood.

[16]  J. Sprent,et al.  Lethal graft-versus-host disease across minor histocompatibility barriers in mice. , 1983, Clinics in haematology.

[17]  G. Janossy,et al.  USE OF ANTI-T-CELL MONOCLONAL ANTIBODY OKT3 TO PREVENT ACUTE GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR ACUTE LEUKAEMIA , 1982, The Lancet.

[18]  J. Sprent,et al.  Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow , 1978, The Journal of experimental medicine.

[19]  K. Oshimi,et al.  Differential effects of anti-Fas ligand and anti-tumor necrosis factor alpha antibodies on acute graft-versus-host disease pathologies. , 1998, Blood.

[20]  K. Koretz,et al.  Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. , 1993, Laboratory investigation; a journal of technical methods and pathology.

[21]  T. Strom,et al.  Anti-Interleukin-2 Receptor Monoclonal Antibody Treatment Prolongs Allograft Survival , 1986 .